Haemato-Oncology

I am a Research Technician with over 10 years of experience in cancer research. I specialise in mouse colony management, genotyping, and supporting day-to-day laboratory work, helping ensure all research projects run efficiently.

I have a long history working of in cancer genetics and with models of paediatric solid tumours. With the aim of developing improved, targeted therapies for high-risk cancers.

I am a PhD student focused on understanding the mechanisms involved in targeting the hypoxia signalling pathway in myeloid malignancies. My work aims to identify synthetically lethal vulnerabilities and resistance mechanisms, with the goal of advancing the clinical translation of novel therapeutic strategies.

I am a MSc student from Leiden University, and I am completing my thesis at the ICR, where I investigate novel therapeutic compounds for acute myeloid leukaemia (AML) by targeting the RNA-binding YTHDF proteins.

I am a senior Post-Doctoral Research Fellow in the Haemato-Oncology Group at the ICR and my research experience to date has focused on genomic profiling, origin and evolutionary aspects of high-risk acute lymphoblastic leukaemia (ALL). Currently, my project explores synthetic lethality concepts and novel drug combinations interfering with mRNA biology using high-risk ALL (T-cell leukaemias) as well as acute myeloid leukaemia (AML) as models.

I am a Senior Staff Scientist at the Centre for In Vivo Modelling (CIVM) and I am specialised in mouse genetics, reproductive technologies and genome engineering, supporting researchers through ICR’s Transgenic, Genome Engineering and Biological Services facilities. My expertise includes in vitro fertilisation (IVF), sperm and embryo cryopreservation, mouse rederivation, gene targeting in embryonic stem cells, and the generation of mouse models using CRISPR technologies.

I am a haematology registrar and second-year PhD student. My clinical and research interests are focussed on AML and improving patient outcomes for this disease. The central aim of my work is to determine how the hypoxia-inducible factor (HIF) pathway can best be stabilised to achieve an optimum anti-leukaemic effect.

I am a Scientific Officer working on drug discovery in acute myeloid leukaemia (AML), with a focus on the 2-oxoglutarate (2OG) oxygenase family. My research explores how these enzymes can be targeted for therapeutic benefit to develop new treatments for blood cancers.

I am a PhD student focused on understanding how RNA-based regulatory mechanisms control gene expression in normal and malignant haematopoiesis. My research aims to explore the wider landscape of RNA modification pathways to identify previously uncharacterised regulators that could offer new therapeutic opportunities in acute myeloid leukaemia (AML).

I graduated with a Bachelor of Engineering (B.E.) in Biotechnology in 2023 and interned at the Himalaya Wellness Company under the Microbiology R&D Department, working on Pharmaceutical, Nutraceutical and Cosmetic Products. After obtaining my MSc degree in Cancer Molecular and Cellular Biology at Queen Mary University of London (Barts Cancer Institute), I am currently conducting laboratory research in Prof Kamil Kranc’s team here at The Institute of Cancer Research (ICR). The project focuses on identifying target vulnerabilities within N^6-methyladenosine (m^6A) RNA methylation reader landscapes in AML cell lines.

I am an experienced researcher carrying out various in vivo models for the Chesler’s and Kranc’s groups. I am currently looking into therapeutic treatment of neuroblastoma, medulloblastoma and AML.

I am a Postdoctoral Research Fellow investigating the role of m6A reader proteins in acute myeloid leukaemia (AML). My principal research objective is to identify therapeutic vulnerabilities and resistance pathways, with the ultimate goal of informing the development of innovative and combinatorial treatment strategies for clinical translation.

I am a Senior Postdoctoral Research Fellow at The Institute of Cancer Research (ICR) in London. My work explores how oxygen sensing, metabolism and hypoxia signalling shape blood cancers like acute myeloid leukaemia (AML). By combining advanced in vivo models, multi-omics and drug discovery, I aim to uncover new, non-toxic ways to eliminate leukaemic stem cells and prevent relapse. My research, published in Nature Cancer and recognised among ICR’s “Top 10 Scientific Achievements,” is now supported by a Blood Cancer UK Project Grant to translate these discoveries into new therapies for patients.

I hold two MSc degrees from the University of Lille, one in Oncology and another one in Bioinformatics, and I am currently a research intern in the Haemato-Oncology Group at the ICR undertaking a volunteer research placement. My work focuses on the RNA metabolism in acute myeloid leukaemia.

My research focuses on RNA biology in normal and malignant haematopoiesis, spanning from the discovery of novel therapeutic targets through to pre-clinical validation of novel compounds. I focus on identifying and exploiting vulnerabilities in acute myeloid leukaemia (AML) to develop more effective and less toxic treatment strategies. In parallel, I investigate how these pathways function in normal haematopoiesis, with a focus on defining therapeutic windows, minimising toxicity, and uncovering new approaches to enhance haematopoietic stem cell transplantation and regeneration.

Since 2016, as a Higher Scientific Officer in the Paediatric Solid Tumour Biology and Therapeutics Group at The Institute of Cancer Research (ICR), I have been investigating the molecular mechanics of aggressive childhood cancers. My research focus on preclinical modelling of high-risk solid tumours, including neuroblastoma and medulloblastoma. I am now incredibly excited to join a new team within Cancer Biology - Haemato-Oncology, where I will be supporting vital in vivo research workflows.